Tuesday, June 20, 2017 8:39:50 AM
SPEX - .948 Pre-market at 1.05/1.19
Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.
Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
